THERAPY DOSSIER · th-91050e046ca6

Neuroectodermal stem cells (NESCs) derived from embryonic day 10 mouse embryo brain

Biologic · Neuroectodermal stem cells from E10 mouse embryo brain; cell therapy.

Evidence & regulatory context

Mechanism: Neuroectodermal stem cells from E10 mouse embryo brain; cell therapy.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30541950 ↗2018Mixed findings

Neuroectodermal stem cells: A remyelinating potential in acute compressed spinal cord injury in rat model.

RatSpinal cord injuryCompressionWistarIntralesional injection at the site of injury using a Hamilton syringe1 day after injury (acute) or 7 days after injury (subacute)

Model: Compressed spinal cord injury

Untreated injury produced haemorrhage, cavitation, reactive astrocytosis, upregulated GFAP, axoplasmic degeneration and demyelination. Grafting NESCs at 1 day after injury reduced the astrocyte reaction and pathological change, enhanced remyelination qualitatively and quantitatively, and improved l…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…